Lucid Diagnostics : Corporate Presentation - March 2024

Nasdaq: LUCD

EsoGuard Esophageal Precancer Testing:

A Breakthrough in Cancer Prevention

March 20, 2024

Lishan Aklog MD

Chairman & CEO

Disclaimer

• This presentation may contain certain forward-looking statements related to or Lucid Diagnostics Inc. (the "Company") that involve risks and uncertainties.
• Actual results and events may differ significantly from results and events discussed in forward- looking statements.
• Factors that might cause or contribute to such differences include, but are not limited to, those discussed in "Risk Factors" in the Company's Annual Reports on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.
• The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made.
• This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
• The Company may not yet have received clearance from the FDA or any other regulatory agency for some of the products described in this presentation.

2

Nasdaq: LUCD

Commercial-stage Cancer Prevention Medical Diagnostics Company

Focused on Early Precancer Detection

MISSION: Prevent Esophageal Cancer Deaths in At-risk Patients

3

High margin asset with

massive market

opportunity

Well-honedmulti-pronged

commercial strategy

Operationally excellent

multidisciplinary field and

laboratory team

World-class leadership team, board and advisors

4

Nasdaq: LUCD

Capitalization

	LUCD Common Stock	Conversion	48.2M
		Price
OUT ST ANDING	Options	$1.74 (avg.)	8.4M
SECURIT IES	Series B Preferred Stock 44,285 shares	$1.24	35.6M
	Secured Convertible Debt	$5.00	2.2M
	Total		94.4M
MARKET	Undiluted		$51M
CAPIT ALIZ AT ION	Fully diluted (Mar 25, 2024; $1.06/shr)		$100M
	Cash 4Q23 ProForma (incl Mar'24 Series B Preferred per above)		$36.3M
	Avg Quarterly Burn Rate thru 4Q23		$8.2M

5

Nasdaq: LUCD

Investment Thesis

• First and only commercially available product addressing large unmet clinical need to prevent esophageal cancer deaths through early precancer detection in well-defined target population as recommended by society guidelines
• ~$60B total addressable market (TAM) with established test pricing and high margins
• Unprecedented diagnostic performance, particularly for early precancer detection
• Growing test volume and near-termreimbursement inflection points, with line of sight to CMS and commercial coverage
• Large additional revenue opportunity through direct contracting, offering test

as covered health and wellness benefit

6

The

Deadly

Three

	5-Year
	Cancer Survival
	Overall		Early
		Stage
Pancreatic
13%	44%
Esophageal	22%	49%
Liver	22%	37%

Esophageal PRECANCER can now be detected

7

Esophageal Cancer - A Ruthless Killer

Over	Incidence Increase
500%	Since 1975

21,560

2023 US Esophageal Cancer Diagnoses

8

Esophageal Cancer

CAN be…

PREVENTED

9

EsoGuard® Esophageal DNA Test

First and only commercially available test capable of serving as a widespread screening tool to prevent esophageal cancer deaths through early detection of

esophageal precancer

10